Cure My Disease

Don't miss your cure!

 Log in / Sign up

Virtual heart program aims to keep patients out of hospital

NCT ID NCT06592508

Disease control Sponsor: Duke University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a remote, virtual cardiology program for people recently hospitalized with worsening heart failure. The program provided education, monitoring, and quick medication adjustments. Researchers compared outcomes like death and repeat heart failure events between those in the program and those receiving usual care. The goal was to see if this virtual approach is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Remote Virtual Cardiology Program (Ventricle Health Program)
What this could lead to
If successful, this virtual program could offer a way to better manage heart failure after hospitalization, potentially reducing deaths and hospital readmissions.
What could go wrong
This is a small, completed study with only 73 participants, so results may not apply to everyone. The program is not a cure and requires ongoing medication and monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

73 people

The number who actually took part.

Started

Sep 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years of age * Acute decompensated HF as a primary cause of hospitalization. Hospitalizations for acute decompensated HF will be determined by local clinician-investigators but should include findings of acute HF (i.e., symptoms, signs, and/or laboratory/imaging abnormalities) and treatments aimed at acute HF (e.g., intravenous diuretics, vasodilators, or inotropes). Participants with a new diagnosis of HF may be enrolled. The enrollment will be monitored to ensure no more than 2/3 of the total cohort has new-onset HF. * Fluent in written and spoken English Exclusion Criteria: * Optimized or nearly optimized on evidence-based medical therapies for HF as determined by local investigator * Current pregnancy * Chronic use of intravenous inotropic medications including milrinone, dobutamine, or dopamine * eGFR of \<20 mL/min/1.73m2 ongoing chronic dialysis at screening. The eGFR should be estimated using the 2021 Chronic Kidney Disease Epidemiology Collaboration (2021 CKD-EPI) creatinine equation. * History of prior heart transplant or currently listed for heart transplant * Current left ventricular assist device or planned left ventricular assist device in the next 6 months * Currently receiving hospice care * Chronically resides in an assisted living or skilled nursing facility where medications are managed by facility personnel * Terminal illness other than HF with a life expectancy of \<1 year as determined by the enrolling clinician-investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure; with decompensation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure; with decompensation

Contacts and locations

Locations

  • Cardiovascular Institute of Northwest Florida

    Panama City, Florida, 32405, United States

  • Duke Raleigh Hospital

    Raleigh, North Carolina, 27609, United States

  • Northeast Georgia Medical Center

    Gainesville, Georgia, 30501, United States

  • Premier Health

    Dayton, Ohio, 45409, United States

  • ProMedica Toledo Hospital

    Toledo, Ohio, 43615, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.